CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer

Title
CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer
Authors
Keywords
Cancer treatment, Ovarian cancer, Chemokines, Angiogenesis, Tumor angiogenesis, Cytokines, Mouse models, Growth factors
Journal
PLoS One
Volume 10, Issue 9, Pages e0139237
Publisher
Public Library of Science (PLoS)
Online
2015-09-29
DOI
10.1371/journal.pone.0139237

Ask authors/readers for more resources

Reprint

Contact the author

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Search

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started